Given the ongoing clinical development and anticipated availability of anti-TIGIT antibodies, combining BCMA-CAR-T therapy with TIGIT blockade may represent a promising strategy to improve clinical outcomes for MM patients. Here, TIGIT is linked to Miyoshi myopathy.